{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:17:14Z","timestamp":1786123034002,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) severely impairs quality of life despite standard surgical and medical therapies. We conducted a network meta-analysis to compare the relative efficacy of biologic agents targeting type 2 inflammation, with a specific focus on how dose and administration frequency influence patient-reported and objective outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology\/Principal<\/jats:title>\n                    <jats:p>A frequentist network meta-analysis was performed across randomized controlled trials evaluating dupilumab, omalizumab, mepolizumab, and benralizumab versus placebo in adults with CRSwNP. Primary outcomes evaluated included sinonasal quality of life (Sino-Nasal Outcome Test-22 [SNOT-22]), objective polyp burden (Nasal Polyp Score [NPS]), and olfactory function (University of Pennsylvania Smell Identification Test [UPSIT]). Interventions were ranked using P-scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixteen randomized controlled trials (4,861 patients) were included. Dupilumab (600\u00a0mg loading dose followed by 300\u00a0mg every 1\u20132 weeks) ranked as the most effective regimen for improving quality of life (P-score = 0.907) and provided the greatest enhancement in olfactory function (P-score = 0.006; Standardized Mean Difference [SMD] = 1.91, 95% confidence interval [CI]: 1.24\u20132.59). Conversely, benralizumab 30\u00a0mg administered every 4 weeks was the top-ranked intervention for reducing objective polyp burden (P-score = 0.864). Substantial heterogeneity and significant global inconsistency were observed within the SNOT-22 (\n                      <jats:inline-formula>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"m1\">\n                          <mml:mrow>\n                            <mml:msup>\n                              <mml:mi>I<\/mml:mi>\n                              <mml:mn>2<\/mml:mn>\n                            <\/mml:msup>\n                            <mml:mo>=<\/mml:mo>\n                            <mml:mn>86.5<\/mml:mn>\n                            <mml:mo>%<\/mml:mo>\n                          <\/mml:mrow>\n                        <\/mml:math>\n                      <\/jats:inline-formula>\n                      ) and NPS (\n                      <jats:inline-formula>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"m2\">\n                          <mml:mrow>\n                            <mml:mfenced open=\"\" close=\")\" separators=\"|\">\n                              <mml:mrow>\n                                <mml:mrow>\n                                  <mml:msup>\n                                    <mml:mi>I<\/mml:mi>\n                                    <mml:mn>2<\/mml:mn>\n                                  <\/mml:msup>\n                                  <mml:mo>=<\/mml:mo>\n                                  <mml:mn>68.9<\/mml:mn>\n                                  <mml:mo>%<\/mml:mo>\n                                <\/mml:mrow>\n                              <\/mml:mrow>\n                            <\/mml:mfenced>\n                          <\/mml:mrow>\n                        <\/mml:math>\n                      <\/jats:inline-formula>\n                      networks, whereas the UPSIT network demonstrated minimal heterogeneity\n                      <jats:inline-formula>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"m3\">\n                          <mml:mrow\/>\n                          <mml:mo>(<\/mml:mo>\n                          <mml:msup>\n                            <mml:mi>I<\/mml:mi>\n                            <mml:mn>2<\/mml:mn>\n                          <\/mml:msup>\n                          <mml:mo>=<\/mml:mo>\n                          <mml:mn>7.5<\/mml:mn>\n                          <mml:mo>%<\/mml:mo>\n                        <\/mml:math>\n                      <\/jats:inline-formula>\n                      ) and remained statistically consistent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biologic efficacy in CRSwNP varies distinctly by clinical endpoint and dosing frequency. Dupilumab optimally drives patient-reported quality of life and olfactory recovery, while intensive benralizumab dosing (every 4 weeks) provides the greatest objective reduction in nasal polyp burden. Therapeutic selection should be personalized to align with individual patient phenotypes and clinical priorities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1772373","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:08:25Z","timestamp":1786108105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of dose and administration schedule on biologic efficacy in chronic rhinosinusitis with nasal polyps: a network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Mostafa A.","family":"Khalifa","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Ahmed Shimal","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Baghdad","place":["Baghdad, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Alexandria University","place":["Alexandria, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakri","family":"Roumi Jamal","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Aleppo","place":["Aleppo, Syria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Atef","sequence":"additional","affiliation":[{"name":"Alexandria Faculty of Medicine","place":["Alexandria, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Sherif","family":"Ali Ahmed","sequence":"additional","affiliation":[{"name":"Mansoura Faculty of Medicine","place":["Mansoura, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khalil","sequence":"additional","affiliation":[{"name":"Dhaka Medical College and Hospital","place":["Dhaka, Bangladesh"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monsurah Bisola","family":"Alatise","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Cadi Ayyad University","place":["Marrakech, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Dway","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Andalus University for Medical Sciences","place":["Tartus, Syria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Raied","family":"Irhayyif","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Baghdad","place":["Baghdad, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101024","DOI":"10.1016\/j.waojou.2024.101024","article-title":"Long-term effects of dupilumab on chronic rhinosinusitis with nasal polyps: a step towards clinical remission","volume":"18","author":"Al-Ahmad","year":"2025","journal-title":"World Allergy Organ. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"","journal-title":"J. Allergy Clin. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"","journal-title":"J. Allergy Clin. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jaip.2020.12.059","article-title":"Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis","volume":"9","author":"Boguniewicz","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/all.16499","article-title":"Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: a meta-analysis of real-world evidence","volume":"80","author":"Cai","year":"2025","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"","journal-title":"Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jaip.2022.02.026","article-title":"Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases","volume":"10","author":"Canonica","year":"","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/03007995.2020.1815682","article-title":"Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis","volume":"36","author":"Chen","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101633","DOI":"10.1016\/j.bjorl.2025.101633","article-title":"Long-term efficacy and safety of different biologics in treatment of chronic rhinosinusitis with nasal polyps: a network meta-analysis","volume":"91","author":"Chen","year":"2025","journal-title":"Braz J. Otorhinolaryngol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S2213-2600(25)00287-5","article-title":"Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial","volume":"13","author":"De Corso","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4193\/Rhin20.600","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"103","author":"Fokkens","year":"2020","journal-title":"Dieudonn\u00e9 Nyenbue Tsh."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29230","article-title":"The effect of dupilumab on intractable chronic rhinosinusitis with nasal polyps in Japan","volume":"131","author":"Fujieda","year":"2020","journal-title":"Laryngoscope"},{"key":"B16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.anai.2023.11.001","article-title":"Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status","volume":"132","author":"Gevaert","year":"2024","journal-title":"Ann. Allergy, Asthma Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/03007995.2024.2434083","article-title":"Dupilumab improves sense of smell and clinical outcomes in patients with severe chronic rhinosinusitis with nasal polyps with anosmia","volume":"41","author":"Lane","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaip.2019.07.016","article-title":"Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis","volume":"8","author":"Maspero","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/alr.23234","article-title":"Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: a systematic review of the current knowledge towards an attempt to compare agents\u2019 efficacy","volume":"14","author":"Papacharalampous","year":"2024","journal-title":"Int. Forum Allergy Rhinol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The joint task force on practice parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaip.2022.01.016","article-title":"Epidemiology of chronic rhinosinusitis: prevalence and risk factors","volume":"10","author":"Sedaghat","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1177\/19458924211009429","article-title":"A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized Anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis","volume":"35","author":"Takabayashi","year":"2021","journal-title":"Am. J. Rhinol. Allergy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/all.16418","article-title":"Endotyping in chronic Rhinosinusitis-An EAACI task force report","volume":"80","author":"Toppila-Salmi","year":"2025","journal-title":"Allergy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double\u2010blind placebo\u2010controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin. & Exp. Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00405-024-08903-7","article-title":"Efficacy of different biologics for treating chronic rhinosinusitis with nasal polyps: a network meta-analysis","volume":"282","author":"Wang","year":"2025","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin22.483","article-title":"Position paper on olfactory dysfunction: 2023","volume":"61","author":"Whitcroft","year":"2023","journal-title":"Rhinology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13223-023-00823-1","article-title":"Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada","volume":"19","author":"Yong","year":"2023","journal-title":"Allergy Asthma Clin. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1772373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:08:27Z","timestamp":1786108107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1772373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1772373"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1772373","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"article-number":"1772373"}}